All Updates

All Updates

icon
Filter
Product updates
KSQ Therapeutics doses first patient in KSQ-001EX clinical development program
Human Gene Editing
Jun 12, 2024
Last week:
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Partnerships
EHang collaborates with KC Smart Mobility to expand EH216-S sales and operations in China
Passenger eVTOL Aircraft
Jul 19, 2024
Industry news
China launches Gaofen-11 high-resolution intelligence satellite
Satellite Management
Jul 19, 2024
Industry news
France funds miniature satellite capture and inspection mission
Satellite Management
Jul 19, 2024
Funding
Partnerships
MyFloraDNA launches crowdfunding campaign to address peanut allergies using CRISPR technology
Crop Biotech
Jul 19, 2024
Partnerships
Ecobloom Technologies partners with Harvest Today to enhance global farming practices
Smart Farming
Jul 19, 2024
Funding
Hyzon Motors announces registered direct offering to raise USD 4.5 million
Truck Industry Tech
Jul 19, 2024
Human Gene Editing

Human Gene Editing

Jun 12, 2024

KSQ Therapeutics doses first patient in KSQ-001EX clinical development program

Product updates

  • Gene editing-based oncology therapeutics developer KSQ Therapeutics has initiated the first patient treatment in a Phase I/II clinical trial of its new candidate, KSQ-001EX. It is a tumor-infiltrating lymphocyte (TIL) therapy with the SOCS1 gene inactivated by CRISPR/Cas9 gene editing, developed as a potential treatment for various solid tumor conditions.

  • The trial is carried out in two phases: Phase I, evaluating the safety and tolerability of KSQ-001EX, and Phase II, evaluating antitumor activity in indication-specific cohorts. The clinical trial is an open-label, safety lead-in study for patients with melanoma, head-and-neck squamous cell carcinoma (HNSCC), and non-small-cell lung cancer (NSCLC).

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.